The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

The Lancet Neurology

Volumn 8, Issue 2, 2009, Pages 151-157

  Ballard, Clive ^a   Hanney, Maria Luisa ^b   Theodoulou, Megan ^c   Douglas, Simon ^d   McShane, Rupert ^e   Kossakowski, Katja ^a   Gill, Randeep ^a   Juszczak, Edmund ^c   Yu, Ly Mee ^c   Jacoby, Robin ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Northgate Hospital   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; PLACEBO; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH CERTIFICATE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE FACILITIES AND SERVICES; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; RISK;

EID: 58649100881     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70295-3     Document Type: Article

References (28)

1. Ferri C.P., Prince M., Brayne C., et al. Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005) 2112-2117
2. Ballard C., and O'Brien J. Treating behavioural and psychological signs in Alzheimer's disease. BMJ 319 (1999) 138-139
3. Gilley D.W., Whalen M.E., Wilson R.S., et al. Hallucinations and associated factors in Alzheimer's disease. J Neuropsych Clin Neurosci 3 (1991) 371-376
4. Rabins P.V., Mace N.L., and Lucas M.J. The impact of dementia on the family. J Am Med Soc 248 (1982) 333-335
5. Ballard C., and Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 7 (2006) 492-500
6. Ballard C., and Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev (Jan 25 2006) CD003476.
7. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 (2006) 191-210
8. Schneider L.S., Tariot P.N., Dagerman K.S., et al. CATIE-AD study group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (2006) 1525-1538
9. Ballard C., Margallo-Lana M., Juszczak E., et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330 (2005) 874
10. Ballard C., Margallo Lana M., Theodoulou M., et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing to take or discontinued from treatment with neuroleptics (the DART-AD trial). PLoS Med 5 (2008) e76
11. Committee for the Safety of Medicines (March 9, 2004). Message from chairman, Committee on Safety of Medicines to medical contacts. Atypical antipsychotic drugs and stroke [memo]. Edinburgh (Scotland): The Scottish Government. http://www.scotland.gov.uk/Publications/2004/03/19074/34348 (accessed Feb 21, 2008).
12. US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. US Food and Drug Administration, FDA Public Health Advisory, Centre for Drug Evaluation and Research 2005. http://www.fda.gov/Cder/drug/advisory/antipsychotics.htm (accessed Feb 21, 2008).
13. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005) 1934-1943
14. Rochon P.A., Stukel T.A., Bronskill S.E., et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 167 (2007) 676-683
15. Koopmans R.T. Are psychotropic drugs too frequently prescribed in Dutch nursing homes?. Tijdschrift voor Gerontologie en Geriatrie 38 (2007) 270-273
16. Margallo-Lana M., Swann A., O'Brien J., et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 16 (2001) 39-44
17. Cohen-Manfield J., Lipson S., Werner P., et al. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 159 (1999) 1733-1740
18. Ballard C.G., Thomas A., Fossey J., et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 65 (2004) 114-119
19. Hollis J., Grayson D., Forrester L., et al. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 15 (2007) 932-941
20. Wang P.S., Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 (2005) 2335-2341
21. Kales H.C., Valenstein M., Kim H.M., et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164 (2007) 1568-1576
22. Livingston G., Walker A.E., Katona C.L., et al. Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study. J Neurol Neurosurg Psychiatry 78 (2007) 25-29
23. Rosen J., and Zubenko G.S. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 29 (1991) 224-232
24. Reilly J.G., Ayis S.A., Ferrier I.N., et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355 (2000) 1048-1052
25. Fossey J., Ballard C., Juszczak E., et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 332 (2006) 756-761
26. Howard R.J., Juszczak E., Ballard C.G., et al. CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357 (2007) 1382-1392
27. Cummings J.L., Schneider E., Tariot P.N., et al. Behavioural effects of memantine in Alzheimer's disease patients receiving donepezil treatment. Neurology 67 (2006) 57-63
28. Pollock B.G., Mulsant B.H., Rosen J., et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 15 (2007) 942-952